Search 

hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

ichorbio is a manufacturer of bulk in vivo antibodies and research biosimilars based in Oxford, United Kingdom.

At ichorbio, their vision is to develop the highest quality reagents to advance scientific research and progress. They believe that the excellence of our products directly impacts the meaningfulness of research outcomes.

As a boutique reagent manufacturer, their target customers are scientists seeking reliable antibodies and other research tools. They aim to provide these products at fair prices - keeping our focus on customers, not shareholders.

Thier best selling in vivo products include RMP1-14, 10F.9G2 and 2.43. Their best selling research biosimilars include mosunetuzumab, odronextamab and aflibercept. Their best selling isotype controls include Rat IgG2a isotype control, Rat IgG2b isotype control, Human IgG1 isotype control and Human IgG4 S228P isotype control. 

IDEA is passionate about getting innovative products to patients with unmet needs and we particularly enjoy putting our full weight of innovative thinking and regulatory expertise behind innovative medicine.

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.

Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.

Our team combines drug discovery specialists with physicists, chemists and computer scientists committed to use cutting-edge technologies to make a difference to people’s lives.

Kuano's approach is to combine state-of-the-art simulation and AI to add quantum detail to structure based drug discovery. Our unique fusion of drug hunting and technology expertise allows us to illuminate new areas of chemical space enabling the design of next generation medicines.

Providing patients with a new way to benefit from Naltrexone

We transform promising life science ideas into medical breakthroughs that change patients’ lives.

Making life science life changing: We transform promising life science ideas into medical breakthroughs that change patients’ lives.

We specialise in early-stage translation – advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures.

Lifescience Industry magazine is a collaboration between regional, national and international life science partners including BioPartner UK.

It includes the latest news and developments from the life science industry, with editorial covering the complete health technology spectrum, as well as funding, trade and collaboration opportunities. 
Currently circulated twice a year to over 40,000 named individuals, it is consistently distributed at key industry events around the world and is available online.

BioPartner members can submit articles free of charge, and receive 15% off all advertising packages.

MedCity is the life sciences cluster organisation for London and the greater south east of England, set up in 2014 by the Mayor of London and the region’s three Academic Health Science Centres. They are funded by the Greater London Authority and Research England, and as a not-for-profit are able to act as a neutral and independent convener across industry, academia and the public sector.

London and the greater south east is home to a rich life sciences cluster, with more than 3,400 life sciences companies, four of the world’s top ten universities, 19 of the top 20 global pharmaceutical companies and world class research centres including The Francis Crick Institute, Harwell Oxford and The Sanger Institute.

MedCity's ambition is for their region to be the unequivocal place of choice for world-leading health and life sciences innovation, R&D, manufacture and commercialisation.